CA Patent

CA3221343A1 — Methods of treating multiple sclerosis

Assigned to Actelion Pharmaceuticals Ltd · Expires 2023-04-20 · 3y expired

What this patent protects

The disclosure relates to methods of treating multiple sclerosis. Also provided are pharmaceutical products containing ponesimod, instructions for use of ponesimod, and methods for reducing clinical management events before or during treatment of multiple sclerosis.

USPTO Abstract

The disclosure relates to methods of treating multiple sclerosis. Also provided are pharmaceutical products containing ponesimod, instructions for use of ponesimod, and methods for reducing clinical management events before or during treatment of multiple sclerosis.

Drugs covered by this patent

Patent Metadata

Patent number
CA3221343A1
Jurisdiction
CA
Classification
—
Expires
2023-04-20
Drug substance claim
No
Drug product claim
No
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.